Clinical trials located in

Koblenz

Koblenz city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Koblenz, nestled at the confluence of the Rhine and Moselle rivers in Germany, boasts a history spanning over 2,000 years. This ancient city is home to the iconic Deutsches Eck, where a monumental equestrian statue of Emperor William I overlooks the river merger. Koblenz’s storied past is encapsulated in the UNESCO-listed Upper Middle Rhine Valley and the Ehrenbreitstein Fortress, accessible via one of the longest cable car rides in Europe. The city’s charming old town, with its narrow lanes and historic buildings, reflects a rich cultural heritage.

  • CT-EU-00057838

    Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

    • povorcitinib
    • ICS-LABA
  • Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    • Astegolimab
  • Studying efficacy of volrustomig for metastatic lung cancer

    The study compared two treatments for metastatic non-small cell lung cancer: volrustomig with chemotherapy and pembrolizumab with chemotherapy. Its purpose is to determine which combination is more effective and safer. Patients will be divided into two groups. One group will receive volrustomig and chemotherapy, and the other group will receive pembrolizumab and chemotherapy. The effectiveness of treatment in each group will then be tracked using imaging tests. In addition, a group of researchers will follow each participant until the end of the study to make sure the treatment is safe and tolerable.

    • Volrustomig
    • Pemetrexed
    • Carboplatin
    • Pembrolizumab
    • Paclitaxel
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    • Pirtobrutinib/LOXO-305
    • Zanubrutinib
    • Ibrutinib
    • Acalabrutinib
  • CT-EU-00057401

    Testing new pressure microcatheter vs traditional pressure wire in heart diseases

    The clinical trial is a research study about two devices that doctors use to measure the severity of a person’s heart problem: a pressure microcatheter and a pressure wire. The new device, a pressure microcatheter, is easier to use and simplifiles pullback maneuvers compared to the pressure wire. The study is done with patients with stable coronary artery disease or stabilised non-ST elevation acute coronary syndrome (ACS) with epicardial stenosis considered for PCI. The goal is to see if using the pressure microcatheter is as good as using the pressure wire. Doctors will use these devices to guide the treatment and improve the heart’s blood flow. The patient will be monitored in the hospital for a year and then checked yearly for five years. The researchers will be evaluating several things including the patient’s health outcomes, the cost and time of the procedure, and the effectiveness of the devices.

  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    • GSK3511294 (Depemokimab)
    • Mepolizumab
    • Benralizumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    • Tanimilast/CHF6001
  • Study new combination therapy in advanced lung cancer

    This study is about testing a new drug mix to help people with advanced lung cancer (NSCLC) that doesn’t have special gene changes. The research aims to determine whether a combination of three drugs, namely Datopotamab Deruxtecan (Dato-DXd), Durvalumab, and Carboplatin, demonstrates superior efficacy compared to an alternative drug mixture. The people in this study have stage IIIB, IIIC, or IV lung cancer. They will be split in two groups. One group will get Datopotamab Deruxtecan, Durvalumab, and Carboplatin. The other group gets Pembrolizumab and some specific chemo drugs. he primary objective is to assess whether the new three-drug combination can effectively delay cancer growth and extend overall survival time.

    • Datopotamab deruxtecan (Dato-DXd)
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Durvalumab
    • Paclitaxel
  • Evaluating depemokimab’s efficacy in severe asthma treatment

    This trial studies the long-term effects of depemokimab in adults and adolescents with severe eosinophilic asthma. Participants who previously joined specific depemokimab studies (206713 or 213744) continue treatment to assess long-term safety and efficacy. The trial monitors adverse events and checks for anti-drug antibodies to evaluate the drug’s sustained effectiveness. The study aims to ensure the safety and prolonged benefit of depemokimab for severe asthma management. It is vital for advancing asthma treatment and improving patient quality of life.

    • GSK3511294 (Depemokimab)
  • New multiple myeloma treatment study with belantamab mafodotin

    This trial investigates belantamab mafodotin in combination with standard treatments (bortezomib, lenalidomide, dexamethasone) for newly diagnosed multiple myeloma. Participants will receive these drugs in varying doses and schedules to evaluate safety, effectiveness, and optimal dosing. The study aims to establish the best dose and schedule for treating multiple myeloma with this combination. This Phase 1 trial is essential for improving treatment options for those newly diagnosed with this type of cancer.

    • Belantamab mafodotin
    • Dexamethasone
    • Lenalidomide
    • Bortezomib
  • Exploring new asthma treatment for adults

    This clinical trial evaluates londamocitinib (AZD4604), a potential new treatment for adults with moderate-to-severe asthma uncontrolled by standard inhalers (ICS-LABA). Participants will receive AZD4604 or a placebo via a dry-powder inhaler over 12 weeks. The trial aims to assess the drug’s effectiveness in managing asthma symptoms and its safety. It focuses on adults whose asthma is not well-controlled by current medications, seeking to offer a new therapeutic option.

    • londamocitinib/AZD4604
  • Study of drug combinations for advanced lung cancer

    This study is about a new combination of medical treatments, Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab and Carboplatin, intended to help people with severe lung cancer (NSCLC). This type of lung cancer lacks specific alterations in its genes that can be targeted by other forms of treatment. The scientists are testing whether this new combination of medicines can be better than another common treatment combination, Pembrolizumab and platinum-based chemotherapy. The researchers will measure the time people can live without their disease getting worse (Progression Free Survival or PFS) and the total time they survive (Overall Survival or OS) to check which treatment is superior. These periods will be monitored with special criterias set up by the medical community. The study will also observe how long people respond to the treatment (Duration of Response or DoR) and how many have an observable reaction to the treatment (Objective Response Rate or ORR). Additionally, they will be analyzing the concentration of Dato-DXd and other components in the blood to inspect the body’s interaction with this treatment.

    • Datopotamab deruxtecan
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Durvalumab
    • Paclitaxel
  • Benralizumab trial for Chronic Lung Disease (COPD) patients

    This Phase 3 clinical trial evaluates Benralizumab in treating COPD, a severe lung condition characterized by breathing difficulties. It specifically targets individuals who experience frequent flare-ups, despite ongoing medication. The trial requires participants to have had at least two flare-ups in the previous year and a high eosinophil count in their blood. The study involves administering Benralizumab for a minimum of 56 weeks, with the aim to assess its impact on reducing flare-ups and improving lung function.

    • Benralizumab
  • Advancing asthma management: study evaluates triple therapy inhaler

    This Phase 3 study evaluates the PT010 inhaler, a combination of budesonide, glycopyrronium, and formoterol, in adults and adolescents with inadequately controlled asthma. The study compares PT010 to standard treatments, assessing its effectiveness in improving lung function and reducing asthma exacerbations. Approximately, 2200 participants will be enrolled and monitored over 24 to 52 weeks. The trial aims to improve asthma management and quality of life for those with persistent symptoms despite current treatments.

    • Formoterol Fumarate
    • Glycopyrronium
    • Budesonide
  • Study of the effects of Durvalumab and Domvanalimab on non-small cell lung cancer

    This study looks at two drugs – Durvalumab and Domvanalimab – and how they may help people with a type of lung cancer that cannot be removed by surgery. These medicines are given to patients after special treatment combining chemotherapy and radiotherapy. The goal is to find out whether these drugs provide benefits and are safe to use. During the trial, patients will be given the real drug or a placebo (a substance that has no therapeutic effect), without knowing which one they will receive. The study will measure how long it takes for the disease to worsen, how long people live and how many people respond positively to treatment. This clinical trial is testing the effectiveness of Durvalumab and Domvanalimab – two drugs – in the treatment of stage III lung cancer that cannot be surgically removed. After undergoing chemotherapy and radiation therapy, participants will be given these drugs to assess their safety. The study is double-blind, meaning neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo. The study will monitor whether the cancer gets worse and what the rate of positive reactions to the drugs is. A study is being conducted with two drugs, Durvalumab and Domvanalimab, for patients with advanced forms of lung cancer that cannot be treated with surgery. After undergoing combined chemotherapy and radiation therapy, participants receive these drugs. The study was designed so that neither the patient nor the doctor knew whether the correct drug or a placebo was being administered. The time until the disease worsens, how long participants live and the number of patients who see improvement with the drugs will be measured.

    • Domvanalimab
    • Durvalumab
  • Research study on COPD treatment with new drug mitiperstat

    This study is testing a new drug, mitiperstat, for people with moderate to severe chronic obstructive pulmonary disease (COPD). It’s a Phase IIa trial where 288 adults will either get mitiperstat or a placebo. This setup allows researchers to compare the effects of mitiperstat against no treatment to determine if it effectively reduces the severity and frequency of COPD symptoms. The aim is to see if mitiperstat can help reduce COPD symptoms and how safe it is. Participants will take the drug or placebo once a day.

    • Mitiperstat
  • Testing new treatment with other drugs for advanced breast cancer

    This study is exploring a new treatment for women with advanced breast cancer. It focuses on patients who have hormone receptor-positive, HER2-negative breast cancer and a specific genetic change (ESR1 mutation). About 300 women will participate. The study compares a new drug, AZD9833 in combination with a group of drugs called CDK4/6 inhibitors (palbociclib, abemaciclib, or ribociclib) with standard treatments (anastrozole or letrozole) in combination with CDK4/6 inhibitor. The aim is to see if AZD9833 works better than standard treatments in stopping cancer from growing.

    • Camizestrant
    • Luteinizing hormone-releasing hormone (LHRH) agonist
    • Abemaciclib
    • Palbociclib
    • Ribociclib
    • Anastrozole
    • Letrozole
  • Myeloma study: lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab

    A groundbreaking study for newly diagnosed multiple myeloma patients is assessing whether a subcutaneous form of the drug isatuximab is as effective as the intravenous version. This study combines isatuximab with three other medications, lenalidomide, dexamethasone and bortezomib, in an approach known as induction therapy. The goal is to enhance patient comfort and maintain treatment effectiveness, potentially leading to an excellent partial response or better in patients eligible for stem cell transplants.

    • Dexamethasone
    • Isatuximab
    • Lenalidomide
    • Bortezomib

See more clinical trials in other cities in Germany:

.